Role of heparin after intravenous thrombolytic therapy for XXXX .

@entity1 @entity662 @entity548 @entity1242 @entity63 @entity741 @entity583 @entity360
The optimal approach to management of @entity1 after thrombolytic therapy for @entity583 ( @entity583 ) is unclear. The role of anticoagulation with heparin was evaluated in 75 consecutive @entity1 who received intravenous streptokinase for @entity583 . Heparin therapy was titrated to keep the partial thromboplastin time (PTT) between 90 and 120 seconds. Seventeen episodes of @entity741 (associated with reversible electrocardiographic changes) were observed in 13 @entity1 . When episodes of probable @entity741 are included (typical @entity662 relieved by @entity1242 or associated with more than a 15-mm Hg change in blood pressure but without electrocardiographic changes), 52 episodes occurred in 28 @entity1 . Four episodes of definite and 4 of probable @entity741 occurred within 24 hours of discontinuation of heparin. Analysis of the level of anticoagulation as assessed by PTT at the time of the @entity63 events shows that @entity63 occurred more often at lower PTTs. Nine @entity548 occurred, all within 24 hours of streptokinase infusion. In 4 @entity1 bleeding was believed to be major and heparin administration was discontinued; 2 @entity1 with @entity360 required blood transfusions. Our data suggest that after thrombolytic therapy for @entity583 , the level of anticoagulation is inversely related to the frequency of recurrent @entity63 events; that discontinuation of heparin is frequently associated with @entity63 ; and that administration of heparin is associated with a low incidence of @entity548 .
